✦ LIBER ✦

Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer's disease: A randomized, double-blind, proof-of-concept study

✍ Scribed by Rinne, J.O.; Wesnes, K.; Hänninen, J.; Murphy, M.; Riordan, H.; Rouru, J.; ALPO Study Group,

Book ID: 123076535
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 60 KB
Volume: 333
Category: Article
ISSN: 0022-510X
DOI: 10.1016/j.jns.2013.07.1199

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting

✍ Pierre N. Tariot; Jeffrey L. Cummings; Ira R. Katz; Jacobo Mintzer; Carlos A. Pe 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB

A long-term, double-blind, placebo-contr

A long-term, double-blind, placebo-controlled efficacy and safety study of nicergoline in patients with mild to moderate Alzheimer's disease

✍ L. Amaducci; K. Maurer; B. Winblad; R. Dom; R. Bullock; L. Bonura; A. Battaglia; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 291 KB

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONT

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

✍ Cummings, Jeffrey; Cho, William; Ward, Michael; Friesenhahn, Michel; Brunstein, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 51 KB

A 24-week, randomized, double-blind, pla

A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease

✍ Nakamura, Yu; Imai, Yukimichi; Shigeta, Masahiro; Graf, Ana; Shirahase, Toru; Ki 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 54 KB

A multicenter, double-blind, randomized

A multicenter, double-blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease

✍ Zimran, Ari; Gonzalez-Rodriguez, Derlis Emilio; Abrahamov, Aya; Elstein, Deborah 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 60 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre